Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Aug

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL